In the 73–10 assay, 59% of patients with TNBC demonstrated CD155 and/or PD-L1 expression in tumor cells, while 39.3% of patients demonstrated only PD-L1 expression in tumor cells. This evidence concerns the gene CD274 and neoplasm.